Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer
Oncotarget2016Vol. 7(22), pp. 33210–33219
Citations Over TimeTop 10% of 2016 papers
Alessandro Passardi, Emanuela Scarpi, Luigi Cavanna, Monia Dall’Agata, Davide Tassinari, Silvana Leo, Ilaria Bernardini, Fabio Gelsomino, Stefano Tamberi, Alba A. Brandes, Elena Tenti, Roberto Vespignani, Giovanni Luca Frassineti, Dino Amadori, Ugo De Giorgi
Abstract
Our results indicate that II, in particular NLR, are good prognostic and predictive markers for mCRC patients who are candidates for CT plus Bev.
Related Papers
- → Bevacizumab 5 or 7.5 mg/kg in Metastatic Colorectal Cancer Can Be Infused Safely Over 10 Minutes(2011)5 cited
- Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer(2012)
- → Two Cases of Leg Ulcer Caused by Bevacizumab(2017)1 cited
- → Bevacizumab Can Be Infused Safely Over 10 Minutes in Metastatic Colorectal Cancer(2014)
- Intracranial hemorrhage in patients treated with bevacizumab：Report of two cases(2011)